Cargando…
Erratum. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. Diabetes Care 2017;40:821–831
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Diabetes Association
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5829961/ https://www.ncbi.nlm.nih.gov/pubmed/29311153 http://dx.doi.org/10.2337/dc18-er03a |
| _version_ | 1783302923600527360 |
|---|---|
| author | Kaul, Sanjay |
| author_facet | Kaul, Sanjay |
| author_sort | Kaul, Sanjay |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5829961 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2018 |
| publisher | American Diabetes Association |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-58299612018-03-22 Erratum. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. Diabetes Care 2017;40:821–831 Kaul, Sanjay Diabetes Care Errata American Diabetes Association 2018-03 2018-01-08 /pmc/articles/PMC5829961/ /pubmed/29311153 http://dx.doi.org/10.2337/dc18-er03a Text en © 2018 by the American Diabetes Association. http://www.diabetesjournals.org/content/licenseReaders may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license. |
| spellingShingle | Errata Kaul, Sanjay Erratum. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. Diabetes Care 2017;40:821–831 |
| title | Erratum. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. Diabetes Care 2017;40:821–831 |
| title_full | Erratum. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. Diabetes Care 2017;40:821–831 |
| title_fullStr | Erratum. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. Diabetes Care 2017;40:821–831 |
| title_full_unstemmed | Erratum. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. Diabetes Care 2017;40:821–831 |
| title_short | Erratum. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. Diabetes Care 2017;40:821–831 |
| title_sort | erratum. mitigating cardiovascular risk in type 2 diabetes with antidiabetes drugs: a review of principal cardiovascular outcome results of empa-reg outcome, leader, and sustain-6 trials. diabetes care 2017;40:821–831 |
| topic | Errata |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5829961/ https://www.ncbi.nlm.nih.gov/pubmed/29311153 http://dx.doi.org/10.2337/dc18-er03a |
| work_keys_str_mv | AT kaulsanjay erratummitigatingcardiovascularriskintype2diabeteswithantidiabetesdrugsareviewofprincipalcardiovascularoutcomeresultsofemparegoutcomeleaderandsustain6trialsdiabetescare201740821831 |